DNA collection, storage, and analysis are crucial in various medical and scientific disciplines. Accurate results hinge on obtaining high-quality, stable samples. While fresh blood samples are traditionally used, they present challenges in collection, transportation, and storage, often rendering them non-viable due to degradation risks.
Dried blood microsampling has emerged as a practical solution for omics research, providing stable DNA and RNA samples without the logistical constraints of fresh blood. This method eliminates many of the limitations associated with wet blood samples, offering a flexible approach suitable for decentralized and remote research settings.
DNA can be extracted from various blood components, with white blood cells (WBCs) being the primary source due to their high nuclear DNA content. Unlike red blood cells, which lack nuclei, WBCs contain intact genetic material, making them ideal for DNA-based studies. Plasma and serum can also contain cell-free DNA (cfDNA), which is particularly valuable in non-invasive prenatal testing (NIPT), cancer research, and infectious disease studies. The ability to extract DNA from different blood fractions broadens the scope of genetic research, allowing for diverse applications in precision medicine.
DNA is typically extracted from cheek cells or white blood cells. While cheek cells are easily accessible, they are prone to contamination. Blood remains the preferred DNA source due to its relative purity. However, wet blood requires careful handling to prevent degradation and involves complex extraction processes that are not always feasible, particularly in field research or resource-limited environments.
Dried blood samples mitigate the stringent time and temperature requirements of wet blood, offering:
Volumetric Absorptive Microsampling (VAMS®) technology overcomes limitations found in traditional dried blood spots on filter paper, which often require labor-intensive extraction processes. VAMS simplifies DNA collection, improving sample consistency and making it more efficient for large-scale studies.
Research confirms that DNA from dried blood spots retains its integrity over extended periods, even when exposed to high humidity or temperatures up to 35°C. Laboratory tests corroborate that there was no significant DNA degradation at 4°C over 24 hours, indicating that extreme cooling is unnecessary for maintaining DNA quality in dried samples.
The advancements in microsampling techniques significantly enhance the viability and accessibility of DNA/RNA collection, especially in non-clinical settings. This method broadens the scope of potential research applications and ensures that genetic analysis remains robust across various environmental conditions.
The Mitra® microsampling device, based on industry-leading VAMS® technology, paired with GenTegraRNA-NEO introduces a cutting-edge RNA stabilization technology that eliminates the need for cold-chain logistics. GenTegraRNA-NEO is an Active Chemical Protection™ (ACP) technology that ensures RNA integrity by safeguarding against environmental stressors and nucleases. This makes it ideal for remote and decentralized research, facilitating high-quality RNA sample collection from broad populations while reducing operational costs.
By integrating GenTegraRNA-NEO with VAMS® microsampling, researchers can confidently collect, stabilize, and transport RNA without the constraints of traditional cold-chain storage methods.
The advancements in microsampling technology provide researchers with unprecedented flexibility in collecting both DNA and RNA from dried blood samples. Whether in genomics, infectious disease research, or precision medicine, VAMS® and GenTegraRNA-NEO together ensure sample integrity while optimizing workflows.